Investigational Drug Information for Netupitant
✉ Email this page to a colleague
What is the drug development status for Netupitant?
Netupitant is an investigational drug.
There have been 18 clinical trials for Netupitant.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2021.
The most common disease conditions in clinical trials are Vomiting, Nausea, and Breast Neoplasms. The leading clinical trial sponsors are Helsinn Healthcare SA, National Cancer Institute (NCI), and Consorzio Oncotech.
There are ninety US patents protecting this investigational drug and eight hundred and eighty-three international patents.
Summary for Netupitant
| US Patents | 90 |
| International Patents | 883 |
| US Patent Applications | 422 |
| WIPO Patent Applications | 334 |
| Japanese Patent Applications | 87 |
| Clinical Trial Progress | Phase 3 (2021-02-01) |
| Vendors | 61 |
Recent Clinical Trials for Netupitant
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma | Sichuan Cancer Hospital and Research Institute | N/A |
| Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | Guangxi Medical University | Phase 3 |
| Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) | Helsinn Healthcare SA | Phase 4 |
Clinical Trial Summary for Netupitant
Top disease conditions for Netupitant
Top clinical trial sponsors for Netupitant
US Patents for Netupitant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Netupitant | ⤷ Sign Up | Crystalline forms of fosnetupitant | Helsinn Healthcare SA (Lugano/Pazzallo, CH) | ⤷ Sign Up |
| Netupitant | ⤷ Sign Up | Cyclohexyl pyridine derivative | KISSEI PHARMACEUTICAL CO., LTD. (Matsumoto, Nagano, JP) | ⤷ Sign Up |
| Netupitant | ⤷ Sign Up | Method for cancer cell reprogramming | STC.UNM (Albuquerque, NM) | ⤷ Sign Up |
| Netupitant | ⤷ Sign Up | Estrogen-related receptor alpha based protac compounds and associated methods of use | Yale University (New Haven, CT) Arvinas, Inc. (New Haven, CT) | ⤷ Sign Up |
| Netupitant | ⤷ Sign Up | Curcuminoid formulations and related methods of treatment | DESIGNS FOR HEALTH, INC. (Suffield, CT) | ⤷ Sign Up |
| Netupitant | ⤷ Sign Up | Carboxymethyl piperidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (Matsumoto-shi, Nagano, JP) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Netupitant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Netupitant | Australia | AU2016335060 | 2035-10-06 | ⤷ Sign Up |
| Netupitant | Canada | CA2996466 | 2035-10-06 | ⤷ Sign Up |
| Netupitant | China | CN108137626 | 2035-10-06 | ⤷ Sign Up |
| Netupitant | European Patent Office | EP3359547 | 2035-10-06 | ⤷ Sign Up |
| Netupitant | Japan | JP2018531249 | 2035-10-06 | ⤷ Sign Up |
| Netupitant | Japan | JP6880009 | 2035-10-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
